Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05703620

REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.

Conditions: Chronic Kidney Diseases, Heart Failure, End Stage Renal Disease

Sex: All
Ages: 18 Years – 75 Years
Phase: NA
Enrollment: 75
Sponsor: Royal Perth Hospital

Location: Australia

Summary

The is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the Paradise denervation system in CKD, End Stage Renal Disease (ESRD), and Heart failure (HF)

Eligibility Criteria

Inclusion Criteria:Both Male and female patientsAges between 18-75 years of ageIndividual is competent and willing to provide written, informed consent to participate in this clinical study with eitherCKD stage 3a/b orESRD on stable renal replacement therapy orMild to moderate heart failure with reduced ejection fractionExclusion Criteria:Ineligible anatomyPrior treatment with other devices for hypertension including but not limited to ROX Coupler (ROX Medical) , Mobius stent, and/or the CVRx (CVRx Inc) barostimulator device.Individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit.Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis.Individual has clinically significant cardiac structural valvular disease, unless corrected by a properly functional prosthetic valveIndividual has been admitted for inpatient hospitalization for decompensated HF in the previous monthFemale participants of childbearing potential must have a negative pregnancy test prior to treatment.Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.Individual is currently enrolled in another investigational drug or device trial. Note: For the purpose of this protocol, participants involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial.Individual has a disease or condition (aside from CKD, ESRD, and HFrEF) that may limit their life expectancy to < 1 year.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05703620). StuddyBuddy aggregates publicly available trial information.